Cargando…
Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells
Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition stud...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775116/ https://www.ncbi.nlm.nih.gov/pubmed/31578349 http://dx.doi.org/10.1038/s41598-019-50335-5 |
_version_ | 1783456168546402304 |
---|---|
author | Eberl, H. Christian Werner, Thilo Reinhard, Friedrich B. Lehmann, Stephanie Thomson, Douglas Chen, Peiling Zhang, Cunyu Rau, Christina Muelbaier, Marcel Drewes, Gerard Drewry, David Bantscheff, Marcus |
author_facet | Eberl, H. Christian Werner, Thilo Reinhard, Friedrich B. Lehmann, Stephanie Thomson, Douglas Chen, Peiling Zhang, Cunyu Rau, Christina Muelbaier, Marcel Drewes, Gerard Drewry, David Bantscheff, Marcus |
author_sort | Eberl, H. Christian |
collection | PubMed |
description | Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry. We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively. A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment. Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors. Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome. Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity. |
format | Online Article Text |
id | pubmed-6775116 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67751162019-10-09 Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells Eberl, H. Christian Werner, Thilo Reinhard, Friedrich B. Lehmann, Stephanie Thomson, Douglas Chen, Peiling Zhang, Cunyu Rau, Christina Muelbaier, Marcel Drewes, Gerard Drewry, David Bantscheff, Marcus Sci Rep Article Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry. We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively. A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment. Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors. Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome. Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity. Nature Publishing Group UK 2019-10-02 /pmc/articles/PMC6775116/ /pubmed/31578349 http://dx.doi.org/10.1038/s41598-019-50335-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Eberl, H. Christian Werner, Thilo Reinhard, Friedrich B. Lehmann, Stephanie Thomson, Douglas Chen, Peiling Zhang, Cunyu Rau, Christina Muelbaier, Marcel Drewes, Gerard Drewry, David Bantscheff, Marcus Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title | Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title_full | Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title_fullStr | Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title_full_unstemmed | Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title_short | Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells |
title_sort | chemical proteomics reveals target selectivity of clinical jak inhibitors in human primary cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775116/ https://www.ncbi.nlm.nih.gov/pubmed/31578349 http://dx.doi.org/10.1038/s41598-019-50335-5 |
work_keys_str_mv | AT eberlhchristian chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT wernerthilo chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT reinhardfriedrichb chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT lehmannstephanie chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT thomsondouglas chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT chenpeiling chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT zhangcunyu chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT rauchristina chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT muelbaiermarcel chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT drewesgerard chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT drewrydavid chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells AT bantscheffmarcus chemicalproteomicsrevealstargetselectivityofclinicaljakinhibitorsinhumanprimarycells |